Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

被引：29

作者：

Vazquez, Marta ^{[1
]}

Guevara, Natalia ^{[1
]}

Maldonado, Cecilia ^{[1
]}

Guido, Paulo Caceres ^{[2
]}

Schaiquevich, Paula ^{[3
,4
]}

机构：

[1] Univ Republica, Fac Quim, Dept Ciencias Farmaceut, Montevideo, Uruguay

[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Farm, Buenos Aires, DF, Argentina

[3] Hosp Pediat JP Garrahan, Med Precis, Buenos Aires, DF, Argentina

[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina

来源：

BIOMED RESEARCH INTERNATIONAL | 2020年 / 2020卷

关键词：

SEROTONIN REUPTAKE INHIBITORS; P-GLYCOPROTEIN INHIBITION; BLOOD-BRAIN-BARRIER; VALPROIC ACID; IN-VITRO; NEUROPATHIC PAIN; HUMAN LIVER; CANNABIDIOL; METABOLISM; VENLAFAXINE;

D O I：

10.1155/2020/3902740

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

引用

页数：9

共 115 条

[1] Cannabinoid-Opioid Interaction in Chronic Pain
Abrams, D. I.
Couey, P.
Shade, S. B.
Kelly, M. E.
Benowitz, N. L.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (06) : 844 - 851
[2] Abubakar AR., 2015, NATL J PHYSL PHARM P, V5, P343, DOI [10.5455/njppp.2015.5.2005201557, DOI 10.5455/njppp.2015.5.2005201557]
[3] Alsherbiny MA, 2019, MEDICINES, V6, P1, DOI DOI 10.3390/medicines6010003
[4] Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
Andreae, Michael H.
Carter, George M.
Shaparin, Naum
Suslov, Kathryn
Ellis, Ronald J.
Ware, Mark A.
Abrams, Donald I.
Prasad, Hannah
Wilsey, Barth
Indyk, Debbie
Johnson, Matthew
Sacks, Henry S.
[J]. JOURNAL OF PAIN, 2015, 16 (12) : 1221 - 1232
[5] Drug interactions with cannabinoids
Antoniou, Tony
Bodkin, Jack
Ho, Joanne M. -W.
[J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (09) : E206 - E206
[6] Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
Baldo, Brian A.
[J]. ARCHIVES OF TOXICOLOGY, 2018, 92 (08) : 2457 - 2473
[7] Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays
Baltes, Steffen
Fedrowitz, Maren
Tortos, Carlos Luna
Potschka, Heidrun
Loescher, Wolfgang
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01) : 331 - 343
[8] A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, Howard N.
Wesche, David
Miller, Raymond
Chapel, Sunny
Janiczek, Nancy
Burger, Paula
[J]. CLINICAL PHARMACOKINETICS, 2010, 49 (10) : 661 - 669
[9] Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Brown, Joshua D.
Winterstein, Almut G.
[J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07):
[10] ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
Brzozowska, Natalia
Li, Kong M.
Wang, Xiao Suo
Booth, Jessica
Stuart, Jordyn
McGregor, Iain S.
Arnold, Jonathon C.
[J]. PEERJ, 2016, 4

← 1 2 3 4 5 6 7 8 9 10 →